{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-079669","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.458177+00:00","generated_at":"2026-05-31T23:59:38.407085+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Akari Therapeutics shareholders approve all proposals at adjourned 2024 AGM","bullets":["Initial June 27 meeting lacked quorum; adjourned to June 28.","All nine ordinary resolutions passed, including re-election of five directors.","Ratified BDO USA as independent auditor and Haysmacintyre as statutory auditor.","Non-binding advisory vote favored annual frequency for say-on-pay.","Votes in favor ranged from 5.7B to 6.5B of ~15.8B outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-079669","json":"https://secwatch.observer/filing/0000950170-24-079669.json","markdown":"https://secwatch.observer/filing/0000950170-24-079669.md","text":"https://secwatch.observer/filing/0000950170-24-079669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024079669/0000950170-24-079669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024079669/aktx-20240628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:59:38.407085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}